# Hyperpolarized 13C MRI for Cancer Immunotherapy

> **NCT05805358** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Chang Gung Memorial Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Gynecologic Cancer
- Cervical Cancer
- Endometrial Cancer
- Ovarian Cancer

## Interventions

- **DRUG:** Hyperpolarized 13C-Pyruvate injection

## Key facts

- **NCT ID:** NCT05805358
- **Lead sponsor:** Chang Gung Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-11-01
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2023-08-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05805358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05805358, "Hyperpolarized 13C MRI for Cancer Immunotherapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05805358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*